Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study

Magliocco, Fabio; Filippis, Renato de; Aloi, Matteo; Staltari, Filippo Antonio; Gaetano, Raffaele; Segura-Garcìa, Cristina; Fazio, Pasquale De

doi:10.1080/13651501.2020.1737134

Cited by 15 publications

(26 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Correlation analysis was carried out to evaluate the relationship between subsequent cognitive decline after two years of antipsychotic treatment and baseline gGMV/ gFCD in the drug-naïve first-episode schizophrenia with 1 ≥ wGMV < 2% at baseline in the moderate whole-brain alteration group. Previous studies reported that some of antipsychotic agents, especially second generation antipsychotics, can improve the cognitive function of the patients with schizophrenia (92)(93)(94)(95)(96). Unfortunately, the schizophrenia patients in the present study who received treatment with the second generation antipsychotic agents according to the schizophrenia treatment guideline did not demonstrated improvement of cognitive function.…”

Section: Discussioncontrasting

confidence: 68%

Baseline global brain structural and functional alterations at the time of symptom onset can predict subsequent cognitive deterioration in drug-naïve first-episode schizophrenia patients: Evidence from a follow-up study

Zhuo

Chen

et al. 2022

Front. Psychiatry

View full text Add to dashboard Cite

Alterations in the global brain gray matter volume (gGMV) and global functional connectivity density (gFCD) play a pivotal role in the cognitive impairment and further deterioration in schizophrenia. This study aimed to assess the correlation between alterations in the gGMV and gFCD at baseline (ΔgGMV and ΔgFCD), and the subsequent alterations of cognitive function in schizophrenia patients after 2-year antipsychotic treatment. Global-brain magnetic resonance imaging scans were acquired from 877 drug-naïve, first-episode schizophrenia patients at baseline and after two years of antipsychotic treatment with adequate dosage and duration, and 200 healthy controls. According to ΔgGMV at baseline, schizophrenia patients were divided into mild, moderate, and severe alteration groups. The MATRICS consensus cognitive battery and Global Deficit Score (GDS) were used to assess cognitive impairment. We found that ΔgGMV and ΔgFCD at baseline were significantly correlated with the severity of the cognitive deterioration (ΔGDS). The correlation coefficient indicated a significant positive correlation between baseline ΔgFCD and subsequent cognitive deterioration, with a relatively stronger relation in the mild alteration group (r = 0.31). In addition, there was a significant positive correlation between baseline ΔgGMV and subsequent cognitive deterioration, with a stronger relation in the moderate and severe alteration groups (r = 0.303; r = 0.302, respectively). Our results showed that ΔgGMV and ΔgFCD are correlated with the severity of cognitive deterioration after completion of a 2-year antipsychotic treatment in schizophrenia patients. These findings suggest that baseline alterations in gGMV and gFCD hold potential for predicting subsequent cognitive decline in schizophrenia.

show abstract

Section: Discussioncontrasting

confidence: 68%

Baseline global brain structural and functional alterations at the time of symptom onset can predict subsequent cognitive deterioration in drug-naïve first-episode schizophrenia patients: Evidence from a follow-up study

Zhuo

Chen

et al. 2022

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

“…Finally, only the study by [ 69 ] presented results on the effectiveness of LAI risperidone in a retrospective cohort study vs. all-oral SGAs and FGAs and vs. oral risperidone [ 69 ]. All the studies, including patients treated with PP1M, reported significant improvements in subjective well-being and global satisfaction, and improved personal and social performance [ 59 , 65 , 67 , 68 , 70 , 71 , 72 , 74 , 75 , 76 , 78 , 79 , 82 ]. Furthermore, functionality improvement was more remarkable in patients with a disease duration of 5 years or less [ 75 ].…”

Section: Resultsmentioning

confidence: 99%

“…Finally, in a longitudinal prospective study, Ref. [ 79 ] reported that PP1M and once-monthly aripiprazole LAI improved social and cognitive functioning in patients who had already experienced relief compared with the corresponding oral formulations of SGAs [ 79 ]. In addition, a few studies reported that high doses of PP1M (175 mg equivalent/28 days) in patients with severe schizophrenia improved the drug’s effectiveness [ 71 ].…”

Section: Resultsmentioning

confidence: 99%

“…Additionally, patients enrolled in other studies showed a low dropout rate, reduced acute healthcare use, and significantly improved neurocognitive function after 12 months of treatment with LAI SGAs, besides better effects on positive, negative, and affective symptoms, psychosocial functioning, and quality of life [ 79 , 82 ]. Furthermore, the transition from PP1M to PP3M evidenced a substantial decrease in combined medications and healthcare resource use, and increased adherence [ 74 ].…”

Section: Resultsmentioning

confidence: 99%

“…Treatment with once-monthly aripiprazole LAI improved BPRS and CGI-S scores, especially in younger patients (age ≤ 35 years) [ 71 ] and was less likely to be associated with discontinuation of treatment when compared with the corresponding oral group or other SGAs [ 65 , 72 , 73 , 77 , 79 , 80 , 81 ]. Thus, adherence and the hospitalization rate appeared to be improved.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Second-Generation Antipsychotics’ Effectiveness and Tolerability: A Review of Real-World Studies in Patients with Schizophrenia and Related Disorders

Fabrazzo

Cipolla

Camerlengo

et al. 2022

JCM

View full text Add to dashboard Cite

Despite methodological limitations, real-world studies might support clinicians by broadening the knowledge of antipsychotics’ (APs) effectiveness and tolerability in different clinical scenarios and complement clinical trials. We conducted an extensive literature search in the PubMed database to evaluate the effectiveness and tolerability profiles of second-generation antipsychotics (SGAs) from real-world studies to aid clinicians and researchers in selecting the proper treatment for patients with schizophrenia and related disorders. The present review evidenced that SGAs demonstrated superior effectiveness over first-generation antipsychotics (FGAs) in relapse-free survival and psychiatric hospitalization rate and for treating negative symptoms. Persistence and adherence to therapy were higher in SGAs than FGAs. Most studies concluded that switching to long-acting injectables (LAIs) was significantly associated with a lower treatment failure rate than monotherapy with oral SGAs. Considerable improvements in general functionality, subjective well-being, and total score on global satisfaction tests, besides improved personal and social performance, were reported in some studies on patients treated with LAI SGAs. Clozapine was also associated with the lowest rates of treatment failure and greater effectiveness over the other SGAs, although with more severe side effects. Effectiveness on primary negative symptoms and cognitive deficits was rarely measured in these studies. Based on the data analyzed in the present review, new treatments are needed with better tolerability and improved effectiveness for negative, affective, and cognitive symptoms.

show abstract

Compatibility studies with pharmaceutical excipients for aripiprazole–heptakis (2,6-di-O-methyl)-β-cyclodextrin supramolecular adduct

Tănase

Sbârcea

Ledeţi

et al. 2020

J Therm Anal Calorim

View full text Add to dashboard Cite

Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study

Cited by 15 publications

References 37 publications

Baseline global brain structural and functional alterations at the time of symptom onset can predict subsequent cognitive deterioration in drug-naïve first-episode schizophrenia patients: Evidence from a follow-up study

Baseline global brain structural and functional alterations at the time of symptom onset can predict subsequent cognitive deterioration in drug-naïve first-episode schizophrenia patients: Evidence from a follow-up study

Second-Generation Antipsychotics’ Effectiveness and Tolerability: A Review of Real-World Studies in Patients with Schizophrenia and Related Disorders

Compatibility studies with pharmaceutical excipients for aripiprazole–heptakis (2,6-di-O-methyl)-β-cyclodextrin supramolecular adduct

Contact Info

Product

Resources

About